Materials and Methods

Yeast strains, cell growth and genetic manipulation
Yeast strains used in this study (Table S1) were grown on YP (yeast extract, peptone) rich or synthetic complete (SC) minimal medium, containing 2% (w/v) of galactose or glucose and supplemented with required auxotrophic markers (39). Galactose-regulatable strains were grown for 40 or 64 h on glucose-containing minimal medium to reduce expression to physiologically critical levels. Except for the experiments with deletion strains, which were derived from Saccharomyces cerevisiae BY (Open Biosystems), all experiments used S. cerevisiae strain W303-1A as reference wild-type strain. For deletion of MMS19 the coding region was replaced with the S. pombe HIS3 marker generated through a PCR fragment using pFA6a-HIS3MX6 as a template (40) .
Regulatable yeast strains in which the levels of Mms19 can be decreased were generated by exchanging the endogenous promoter of MMS19 for the GAL1-10 promoter or for a truncated version thereof (GalL; (41) ). Growth of yeast cells in the presence of galactose leads to expression of MMS19, while cultivation in glucose-containing medium depletes the protein strongly (30) . Exchange of the endogenous MMS19 for the various Gal promoters by homologous recombination during construction of the GalL-MMS19, GalL-HA-MMS19 or Gal-GFP-MMS19 strains was accomplished by using a cassette amplified from plasmids pYM-N27, pYM-N28 or pYM-N25 as templates, respectively (41) . Primers contained 20 nucleotides of the template and nucleotides 113,756-113,806 or 113,808-113,853 of chromosome IX. Correct integration was confirmed by PCR reactions of chromosomal DNA amplifying the TAO3-MMS19 intergenic and NAT-MMS19 (nourseothricin acetyl transferase) region. For exchange of the RAD3 promoter by the GalL promoter during construction of the GalL-HA-RAD3 strain plasmid pYM-N28 was used as a template to amplify the cassette for homologous recombination. Primers contained 20 nucleotides of the template and nucleotides 526,759-526,808 or 527,078-527,127 of chromosome V. Correct integration was confirmed by PCR amplification of chromosomal DNA in the ADK2-RAD3 intergenic and NAT-RAD3 regions.
The yeast RAD3 gene was PCR amplified from chromosomal DNA with primers introducing NheI and NcoI restriction sites, and cloned into the SpeI and NcoI sites of p424-TDH-TAP (C-terminal) (42) . Using human cDNA cloned into pCMV-SPORT6 by the IMAGE consortium (MGC 102762), the XPD gene was PCR-amplified with primers introducing SpeI and BglII sites, and cloned into the SpeI and BamHI sites of p424-TDH-TAP. XPD mutagenesis (see Table S2 for plasmids) was carried out with the p424-TDH-XPD-TAP plasmid as template. Primers designed according to (43) introduced restriction sites with silent mutations given by the Watcut tool (http://watcut.uwaterloo.ca/) from Michael Palmer (University of Waterloo, Canada). All plasmid constructs were sequenced. 55 Fe incorporation into Fe/S proteins Appropriate plasmids were transformed into various S. cerevisiae W303 derivatives. After growth of cells on galactose-or glucose-containing SC medium for 24 h (or 48 h with dilution after 24 h), cells were grown in iron-poor (no added iron) SC medium for 16 h. Δyfh1 cells were only grown on glucose. Precipitation of the 55 Fe associated with the Fe/S proteins was performed as described earlier using IgG-Sepharose, Protein A-Sepharose (coated with specific antibodies), or anti-HA Agarose (30) . Depletion of proteins and immunoprecipitation from cell extracts was analyzed by SDS-PAGE and immunostaining. Monoclonal antibodies against Myc-or HA-epitopes were from Santa Cruz. Polyclonal antibodies against various yeast proteins were raised in rabbits in the Marburg laboratory (44) .
DNA damage reporter assays
Hyperphosphorylation of the yeast Rad53 protein was used as a marker for DNA damage (36) . Yeast cells were first depleted for various ISC and CIA proteins by growth in glucosecontaining SC medium. During the final growth step MMS (methyl methanesulfonate) was added at the indicated concentrations. Cell extracts were prepared under denaturing conditions (36) and separated by 8% acrylamide SDS-PAGE (50 µg protein/lane). After overnight tank blotting onto PVDF membranes phosphorylated Rad53 was detected by specific monoclonal antibodies (F9) generously supplied by Drs. A. Pellicioli and M. Foiani.
Another yeast DNA damage reporter assay employed Photinus pyralis luciferase under the control of well-characterized yeast DNA-damage inducible promoter regions in centromeric plasmids (p414). Promoter regions (750 bp at the 5' side of the start codon) of the HUG1 and RNR3 genes were amplified from yeast chromosomal DNA and cloned into the SacI/NcoI site of p414-LUX. The plasmids were transformed into wild-type yeast cells and luminescence from luciferase in cell extracts was determined with a Tecan Infinite M200 microtiter plate reader. To the cell extracts (5 µL, 1-2 µg protein) 20 µL firefly luciferase reagent (Promega) was added. The signal response of the p414-HUG1-LUX and p414-RNR3-LUX reporter plasmids was optimal at 0.25 mM MMS. Luciferase activities (arbitrary luminescence intensities per mg soluble protein) were normalized to the response of wild-type cells grown under identical conditions. UV-and MMS-induced DNA damage was estimated using human HEK293 cells. Stable shRNA expressing cells (see section describing lentiviral stable knockdown cell lines) were induced with doxycycline for 12 days. Equal numbers of cells were plated for each cell line and grown overnight. Medium was then removed and cells were treated with 20 J/m 2 of UV light (CL-1000 Ultraviolet Crosslinker from UVP, LLC, Upland, CA) with the lid removed. Fresh media was added to the cells after UV treatment and cells were grown for 7 days before cell viability was measured using the MTS assay (Promega). Similarly, 20 μM MMS (Acros Organics, New Jersey, USA) was added to the different stable knockdown cell lines and cell viability was assessed using MTS assay 7 days later. The MTS assay reagent was made by dissolving CellTiter 96 R Aqueous MTS (G1112; Promega) powder at a concentration of 2 mg/mL in 1x PBS containing 300 μM phenazine ethosulfate (PES) (MP Biomedicals). The MTS assay reagent was added to cells at a final concentration of 20%. Cells were incubated for 3 h at 37°C before absorbance of the sample was read at 490 nm. All absorbance values were averaged for control and treated samples.
Small interfering RNAs
Silencer ® Select siRNAs against human mRNAs of MMS19 and frataxin (Table S3) as well as scrambled siRNAs (Silencer ® select negative controls #1 and #2) were purchased from Ambion. Double-stranded siRNA si#3 (s34551) against MMS19 contained a mismatch (highlighted in Table S3 ) and thus served as an internal negative control.
Plasmids used in human tissue culture A plasmid containing MMS19 was kindly provided by Lurdes Queimado. The MMS19 ORF was using primers containing AttB sites with Phusion Taq polymerase (NEB) and subcloned into pDONR221 vector using the Gateway cloning system (Invitrogen). The Gateway cloning system was also used to transfer genes into Gateway-adapted expression plasmids that encode 3xHA-3xFLAG.
Quantitative real-time PCR Total RNA from snap-frozen HeLa cell samples was prepared using the peqGOLD RNApure reagent (Peqlab). Complementary DNA (cDNA) was amplified by means of the RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas). Quantification of cDNA was performed using a Cepheid Smart Cycler II (Intas, Göttingen, Germany) and the Maxima® SYBR® Green/ROX qPCR Master Mix (Fermentas). MMS19 expression was quantified using the primer pair CTGTGCTGGCTTCTACACCA / ACACAGCACAGCAAG CATTC, while beta-actin expression was determined by the primer pair CTCTTCCAGCCTT CCTTCCT / AGCACTGTGTTGGCGTACAG.
Antibodies and immunoprecipitation
MMS19 antiserum was raised in the Lill laboratory ( fig. S5B ), as well as obtained from Proteintech Group, Inc. (Chicago, IL, USA; fig. S12 ). Antibodies against beta-actin, DPYD, RTEL1, XPB, XPD, and c-Myc came from Santa Cruz biotechnology (Santa Cruz, USA). POLD1 antibodies were obtained from Santa Cruz biotechnology or from Proteintech, and FANCJ antibodies from Bethyl Laboratories; ISCU and Fam96B antibodies were purchased from Proteintech; mouse anti-Complex II (30 kDa Fe/S protein subunit SDHB) mab was purchased from MitoSciences; CIAO1 antiserum (UCLA852) was raised in the Wohlschlegel Laboratory; antibodies against NARFL/IOP1, FLAG-M2, and β-tubulin were bought from Sigma; affinitypurified rabbit anti-murine GPAT serum was kindly provided by H. Puccio, Illkirch Cedex, France; monoclonal mouse anti-IRP1 mab (clone 295B) and rabbit anti-IRP2 serum were kindly provided by R. Eisenstein, Wisconsin, USA; rabbit serum against human MIA40 was kindly provided by J. Herrmann, Kaiserslautern, Germany; rabbit anti-mitochondrial aconitase serum was kindly donated by L. Szweda, USA. Peroxidase-conjugated goat anti-rabbit and anti-mouse antibodies were used as secondary reagents upon immunoblotting.
Immunoprecipitation and immunoblotting was performed as described (35) . For FLAG immunoprecipitations, affinity matrices for anti-FLAG M2 were used. For endogenous immunoprecipitation, antibodies were pre-bound to equilibrated GammaBind TM Plus Sepharose TM (GE healthcare) for 1 h and then washed three times with lysis buffer to remove unbound antibody. Equal amounts of protein lysate were added to the beads and incubated for 2 h at 4°C. Beads were washed three times with lysis buffer and then suspended in 2x SDS loading buffer. Samples were further analyzed by SDS-PAGE followed by immunoblotting with relevant antibodies.
Tissue culture, cell lines and transfection Human cervix carcinoma cells (HeLa) were maintained in Dulbecco's Modified Eagles medium (DMEM) containing 4.5 g/L glucose and supplemented with 7.5% fetal calf serum, 1 mM glutamine, and 100 units/mL penicillin and 100 µg/mL streptomycin. Upon transfection by electroporation 4 to 8 × 10 6 HeLa cells were resuspended in 525 µL transfection buffer (21 mM Hepes, pH 7.4, 137 mM NaCl, 5 mM KCl, 0.7 mM Na 2 HPO 4 , and 6 mM dextrose) and supplemented either with a pool or with individual siRNAs amounting to a total of 15 µg RNA.
In order to prolong the time period of mRNA depletion cells were retransfected twice at three day intervals. Protein content of harvested cells was determined by the Bradford method (Biorad).
HEK cell lines were cultured in DMEM containing 10% fetal calf serum (Foundation B FBS from Gemini), 100 units/mL penicillin and streptomycin, and 2 mM glutamine at 37°C in ambient air with 5% CO 2 Viruses for each target gene knockdown were collected after 48 and 72 h post transfection. HEK293 cells were infected with viruses as described by the manufacturer (Thermo Scientific). Media were exchanged 6-8 h after infection. Stable integrants were selected by the addition of puromycin (1 μg/mL) 48 h after infection for one week while changing media and adding fresh puromycin at 2-3 day intervals. The selected colonies were induced with doxycycline (1 μg/mL) for 12 consecutive days to turn on shRNA expression and attain sustained depletion of the genes of interest. Fresh doxycycline was added to the culture media every 24 h.
Enzyme activity measurements and HeLa cell fractionation
The enzyme activity of dihydropyrimidine dehydrogenase (DPYD) was determined by thin layer chromatography (TLC) using a combination of several published protocols (45) (46) (47) (48) . In short, a HeLa cell sample corresponding to 125-250 µg protein was applied to 25-50 µL of a reaction mixture containing 25 mM Tris-HCl (pH 7.5), 0.08% digitonin, 2.5 mM MgCl 2 , 2 mM DTT, 10-30 µM [4- 14 C]-thymine (59 mCi/mmol, Hartmann Analytic, Germany), up to 5 mM NADPH, as well as 5 mM glucose-6-phosphate (G6P) and 1 U/mL G6P-dehydrogenase to regenerate NADPH. After 4 h of incubation at 32.5°C the reaction was stopped by addition of 10 µL of perchloric acid (10% v/v). Reaction mixtures were centrifuged at 15,000 ×g for 5 min and supernatants were analyzed by TLC. Plastic TLC sheets pre-coated with 0.1 mm cellulose MN 300 (Macherey-Nagel, Germany) were pre-run with the organic phase of a nbutanol:water:ammonium hydroxide (90:45:15, v/v/v) mixture. Six microliters of the final sample were spotted onto a dried TLC plate, separated by three consecutive developing steps with intermittent drying, and analyzed by autoradiography.
Digitonin-based cell fractionation of HeLa cells, as well as measurements of aconitase, succinate dehydrogenase (SDH), lactate dehydrogenase (LDH), and citrate synthase (CS) activities were performed as described (16, 49) . Binding of IRP1 to IREs present in ferritin mRNA was examined by REMSA (16, 50) .
Affinity purification of human MMS19 for proteomic analysis
Twelve 15 cm tissue cultures plates of 3xHA-3xFLAG MMS19-expressing Flp-In TM TREx TM -293 cells were grown, induced with doxycycline overnight, harvested and lysed in IP buffer (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 5% glycerol, 0.1% NP-40, 1 mM DTT, 0.5 mM PMSF, 1 μM pepstatin, 1 μM leupeptin and 2 μg/mL aprotinin). 200-300 mg of clarified protein lysate was then incubated with 100 μL of equilibrated anti-FLAG M2 agarose beads (Sigma) for 2 h at 4°C. Beads were washed four times with 1 mL of IP buffer per wash before eluting with two sequential steps of 500 μL using FLAG elution buffer (IP buffer without NP-40 supplemented with 250 μg/mL of 3xFLAG peptide (Sigma)). These eluted fractions were pooled and precipitated by the addition of trichloroacetic acid (TCA) to a final concentration of 20% followed by incubation on ice for 60 min and centrifugation at 16,000 xg for 30 min to collect the precipitate. The final precipitate was washed twice with acetone and air dried prior to further analysis.
Identification of human MMS19 associated protein complexes by MudPIT analysis
TCA-precipitated samples of affinity-purified 3xHA-3xFLAG-MMS19 were proteolytically digested and analyzed by MudPIT, a shotgun proteomic approach in which the entire peptide mixture is fractionated online using a combination of strong cation exchange and reversed phase chromatography and eluted directly into the mass spectrometer where MS/MS spectra are collected (51, 52 ). An online 5-step multidimensional chromatographic separation was performed and fractionated peptides were eluted directly into a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher) where tandem mass spectra were collected. Peptide mass spectra were analyzed using the SEQUEST and DTASelect algorithms (53) . False positive rates were estimated using a decoy database approach and results filtered such that only proteins identified by two different peptides using peptide-level false positive rate of 5% were considered present in the sample (54) . Proteins were treated as putative MMS19-associated proteins, if they were identified in the relevant affinity purification but not in a previously generated database of proteins that bind nonspecifically to FLAG M2 beads. Table S4A contains a curated list of MMS19-interacting proteins identified in this analysis that are known or putative Fe/S proteins or CIA machinery components. Table S4B contains the complete set of putative MMS19-interacting proteins ranked according to their normalized spectral abundance values (NSAFx10 5 ) (55) . A detailed description of the multidimensional peptide fractionation protocol, mass spectrometer settings, and bioinformatic workflow has been published elsewhere (56) .
Statistics
All values reported are expressed as the mean ± standard deviation (SD). Pairwise comparisons of data were calculated according to Student's T-test, while comparisons of multiple data sets were analyzed by variance analysis (ANOVA) followed by appropriate post-hoc tests. This study
Supplementary Tables
Gal-NFS1
W303-1A pNFS1::GAL10HIS3 (PCR fragment obtained with pFA6a-HIS3MX6-Gal1-10)
Gal-YAH1 
Gal-SSQ1
W303-1A pSSQ1::GAL110LEU2 (PCR fragment obtained with pTL26) (61) GalL-HA-DRE2
W303-1A pDRE2::natNT2GALL3HA (PCR fragment obtained with pYM-N28)
GalL-HA-TAH18
W303-1A pTAH18::natNT2GALL3HA (PCR fragment obtained with pYM-N28)
Gal-CFD1
W303-1A pCFD1::GAL110HIS3 (PCR fragment obtained with pFA6a-HIS3MX6-Gal1-10) (19) Gal-NBP35
W303-1A pNBP35::GAL110HIS3 (PCR fragment obtained with pFA6a-HIS3MX6-Gal1-10)
Gal-NAR1
W303-1A pNAR1::GAL110HIS3 (PCR fragment obtained with pFA6a-HIS3MX6-Gal1-10) (20) Gal-CIA1
W303-1A pCIA1::GAL110HIS3 (PCR fragment obtained with pFA6a-HIS3MX6-Gal1-10) (19) BY4742 (wild-type) Abbreviations: C, C-terminal. All promoters and proteins are from yeast, except for luciferase (firefly) and XPD (man). Abbreviations: NSAF, normalized spectral abundance factor: PE, protein existence; SV, sequence version. Fig. S1 .
Supplementary Figures
Interaction of yeast Mms19 with CIA factors and Fe/S proteins. (A)
Gal-GFP-MMS19 yeast cells were transformed with plasmids encoding Cia2-HA, Cia1-HA, Nar1-HA, or no insert (-). Cell extracts (CE) prepared from an overnight culture grown in SC galactose medium were immunoprecipitated using anti-HA beads. Cell extracts and immunoprecipitates (IP:HA) were separated by SDS-PAGE, and Mms19 was immunostained using its GFP-tag (IB:GFP). (B) GalL-MMS19 cells were transformed with plasmids encoding Rli1-HA, Ntg2-HA, or Cia1-HA. The non-Fe/S protein Ymr134w-HA (see (19) ) was used as a negative control. Extracts from overnight cultures grown in SC galactose medium were used for immunoprecipitation (IP) with anti-HA beads. Cell extracts (CE) and immunoprecipitates (IP:HA) were analyzed by immunostaining for the indicated proteins with specific antibodies (anti-HA, top; anti-Mms19, bottom). 55 Fe. XPD-TAP and mutant proteins were immunoprecipitated from cell extracts, and bound 55 Fe was quantified by scintillation counting. The immunoblot shows XPD in whole cell extracts. For all depletions p<0.001. (B) Mms19 is required for Fe/S protein maturation of yeast Dna2. GalL-MMS19 cells were transformed with a plasmid encoding Dna2-HA. 55 Fe incorporation (as in A) was measured in cells grown in galactose-(Gal) and glucose-(Glc) containing media. An immunostain of Dna2-HA in cell extracts is shown.
Fig. S5.
Effective depletion of human MMS19 by siRNAs. (A) HeLa cells were transfected thrice at a three day interval without or with individual (diamonds, triangles, and squares) or pooled (▬ ± SD) siRNAs directed against different regions of MMS19 mRNA. 3, 6, and 9 days after the first transfection residual mRNA (left) or protein (right) levels of MMS19 were determined by qRT-PCR or immunoblotting, respectively. The data were normalized to betaactin, and these ratios to the levels of mock-transfected cells (set to 100%). Note that the mismatch-containing siRNA si#3 was ineffective in depleting MMS19 thus serving as an internal control (see Table S3 ). (B) A representative example of the data in (A) is presented for HeLa cells treated for 9 days. Cells were permeabilized with digitonin, and the lysate was separated into supernatant (Cytosol) and pellet (Organelles) fractions showing a predominant cytosolic localization of MMS19. The cytosolic protein β-actin and mitochondrial intermembrane space protein MIA40 were used as controls. Abbreviations: -, mock-treated cells, +, cells treated with the pool of three siRNAs directed against MMS19. fig. S5 ), or with two scrambled siRNAs not targeting any known human RNA (used individually or as a pool) for 3, 6, and 9 days as in fig. S5 . (A) IRP1 (cytosolic aconitase) enzyme activities were measured using the cytosolic fractions (cf. fig. S5B ) by an isocitrate dehydrogenase-coupled NADP + -dependent spectrophotometric assay. Data were normalized to LDH activity, and expressed relative to the activities in mock-transfected cells (set to 100%; dashed line). (B) Total cell lysates were immunostained and the ratio of IRP1 and β-actin was normalized to the respective ratio of mock-transfected cells (dashed line). (C) The IRP1 binding to 32 P-labeled iron-responsive element (IRE) of human ferritin mRNA was analyzed by native gel electrophoresis and subsequent phosphorimaging. IRP2 was super-shifted by specific antibodies to obtain the IRP1 signal only. The IRP1-IRE binding (-β-ME) was calculated relative to the maximum IRP1 binding activity determined in the presence of 2% β-mercaptoethanol (+ β-ME), and a representative example is shown for 9 days of treatment (bottom panel). Data (± SD) were normalized to the respective ratios in mock-transfected cells (dashed line). Total cell lysates from (B) were immunostained and the ratio of protein-associated chemiluminescence for DPYD and β-actin was normalized to the respective ratio of mocktransfected cells (set to 100%; dashed line).
Fig. S8 (ctd.).
(E) HeLa cells were RNAi-depleted for the ISC assembly components NFS1 and frataxin (FXN) and the CIA factor NBP35 (16, 63, 64) . Total cell extracts were immunostained for DPYD and beta-actin and data analyzed as in (D). For all depletions p<0.01, except for day 3 of FXN siRNA treatment. 3D and S5A and analyzed by immunostaining for POLD1, the catalytic subunit of DNA polymerase δ. Normalization of the data was done using beta-actin, and the ratios were presented relative to those in mock-transfected cells (set to 100%; dashed lines). POLD1 levels were strongly affected in cells depleted for MMS19 for 9 days with pooled siRNAs, and virtually no effect was obtained for the non-effective siRNA si#3 (grey squares; cf. fig. S5A ). (B) HeLa cells were RNAi-depleted for the ISC assembly components NFS1 and frataxin (FXN) and the CIA factor NBP35 (16, 63, 64) . Total cell extracts were immunostained for POLD1 and beta-actin and data analyzed as in (A). enzyme activities of mitochondrial aconitase (mtAco), or (C) protein levels (SDHB subunit) and (D) enzyme activities of mitochondrial succinate dehydrogenase (SDH). Protein levels were determined by immunostaining of total cell lysates, and quantitated relative to β-actin levels. Data were normalized to the respective ratio in mock-transfected cells. Aconitase and SDH enzyme activities were measured in the organellar fraction of digitonin-lysed cells, and quantitated relative to citrate synthase (CS) activity. Data were expressed relative to the activities in mock-transfected cells (dashed lines), and presented as in fig. S6 .
Fig. S11.
XPD associates with MMS19 at endogenous concentrations. Endogenous XPD protein was immunoprecipitated from protein extracts derived from HEK293 cells using XPD antibodies. Whole cell extracts (WCE) and immunoprecipitates (IP) were immunostained with specified antibodies. shRNA constructs designed to silence expression of MMS19, FAM96B, IOP1, or ISCU were generated the using the Thermo Scientific TRIPZ Lentiviral shRNAmir system. Cells were induced continuously with doxycycline (1 µg/mL) for 12 days to maintain sustained depletion of the proteins of interest. Cell lysates were prepared and immunostained with the specified antibodies to assess the degree of silencing. Fe/S protein biogenesis requires the mitochondrial ISC assembly machinery, the ABC transporter ABCB7 and the CIA machinery. The CIA component MMS19 is part of the 'CIA targeting complex' that transfers Fe/S clusters from the CIA scaffold complex CFD1-NBP35 to specific Fe/S apoproteins including members involved DNA metabolism. The putative roles of human CIAO1 and FAM96B in the assembly process remain to be elucidated.
